You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Frequently asked questions

Below are examples of frequently asked questions by parents about Infanrix-IPV+Hib.

What does Infanrix-IPV+Hib protect my child against?

This vaccine is a 5-in-1 vaccine. It helps to protect your child against diphtheria, tetanus, whooping cough, polio and Hib disease.

Where is Infanrix-IPV+Hib injected?

The vaccine is injected into the muscle of your child’s thigh.

Is the vaccine safe?

The vaccine has been widely studied in clinical trials and the resulting information has been reviewed by the regulatory authorities around the world. On the basis of all the information provided, these authorities have concluded that the benefits the vaccine brings to children far outweigh any safety concerns.

As with all injectable vaccines, some children may experience redness, pain and swelling at the site of the injection and some may become irritable, go off their food or develop a slight fever. Some children have reportedly developed diarrhoea and vomiting following vaccination and other reactions like widespread rash, allergic reactions, breathing issues and convulsions are unusual, but have been reported.

If your child gets any side effects after vaccination, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard. By reporting side effects you can help provide more information on the safety of this vaccine.

How many children have had the vaccine?

In 2013, 3,725,973 doses of Infanrix-IPV+Hib were used globally, with just under half of these doses given in the EU.

Which other countries use Infanrix-IPV+Hib?

In 2013 the vaccine was used in 26 countries in the EU, including but not limited to France, Germany, Norway, Poland and Romania. Globally 52 countries used Infanrix-IPV+Hib in 2013.

If you have further questions, please talk to your nurse, doctor or pharmacist.  

 

If you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
By reporting side effects you can help provide more information on the safety of this medicine.

Infanrix-IPV+Hib is a registered trademark of the GlaxoSmithKline Group of Companies

LS: last updated December 2015: UK/VAC/0019/14(1)g